Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
Authors
Keywords
-
Journal
Journal of Fungi
Volume 7, Issue 12, Pages 1058
Publisher
MDPI AG
Online
2021-12-10
DOI
10.3390/jof7121058
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
- (2021) John C. Byrd et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
- (2021) Andrew X. Zhu et al. JAMA Oncology
- Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real‐world study
- (2021) Maria Stefania Infante et al. Cancer Medicine
- Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
- (2020) Eytan M Stein et al. Lancet Haematology
- Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia
- (2020) Amanda Tey et al. ANNALS OF HEMATOLOGY
- Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials.
- (2020) Richard R. Furman et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- Non‐ Aspergillus invasive mold infections in patients treated with ibrutinib
- (2020) Amalia Anastasopoulou et al. MYCOSES
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
- (2020) Joshua S. Davis et al. CLINICAL MICROBIOLOGY REVIEWS
- Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib
- (2020) Michael Frei et al. LEUKEMIA & LYMPHOMA
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study
- (2020) Gessica Marchesini et al. BRITISH JOURNAL OF HAEMATOLOGY
- BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
- (2020) Stefania Fiorcari et al. Frontiers in Immunology
- Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
- (2020) Valentina Griggio et al. Frontiers in Immunology
- Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
- (2019) Hareth Nahi et al. PLoS One
- Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
- (2019) Georg Maschmeyer et al. LEUKEMIA
- Aspergillus fumigatus and Aspergillosis in 2019
- (2019) Jean-Paul Latgé et al. CLINICAL MICROBIOLOGY REVIEWS
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody
- (2019) Kristen M. Sarlo et al. LEUKEMIA & LYMPHOMA
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Azole antifungals and new targeted therapies for hematological malignancy
- (2019) Julian Lindsay et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Steven T. Bird et al. JAMA Oncology
- Infections associated with ruxolitinib: study in the French Pharmacovigilance database
- (2018) Pinel Sylvine et al. ANNALS OF HEMATOLOGY
- Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
- (2018) David Ghez et al. BLOOD
- Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies
- (2018) Benjamin W. Teh et al. BLOOD REVIEWS
- Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2018) Matthew S. Davids et al. CLINICAL CANCER RESEARCH
- Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
- (2018) Tilly Varughese et al. CLINICAL INFECTIOUS DISEASES
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
- (2018) L. Drgona et al. CLINICAL MICROBIOLOGY AND INFECTION
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
- (2018) M. Reinwald et al. CLINICAL MICROBIOLOGY AND INFECTION
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)
- (2018) M. Mikulska et al. CLINICAL MICROBIOLOGY AND INFECTION
- Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies
- (2018) Benjamin F. Tillman et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study
- (2018) Véronique Leblond et al. HAEMATOLOGICA
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia
- (2018) Silvia Martinelli et al. HAEMATOLOGICA
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study
- (2018) Véronique Leblond et al. HAEMATOLOGICA
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia
- (2018) Silvia Martinelli et al. HAEMATOLOGICA
- Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
- (2018) Timothy M. Pierpont et al. Frontiers in Oncology
- Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
- (2018) Antonio Cuneo et al. HEMATOLOGICAL ONCOLOGY
- Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
- (2018) Randy A. Taplitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib
- (2018) Matthew P. Cheng et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation
- (2017) Nicole Stadler et al. HAEMATOLOGICA
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis
- (2017) Marine Baron et al. LEUKEMIA & LYMPHOMA
- Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia
- (2017) B. Lafon-Desmurs et al. MEDECINE ET MALADIES INFECTIEUSES
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation
- (2017) Nicole Stadler et al. HAEMATOLOGICA
- Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
- (2017) Alexander N. R. Weber et al. Frontiers in Immunology
- Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia
- (2016) Niklas Vogt et al. ANNALS OF HEMATOLOGY
- Idelalisib in the management of lymphoma
- (2016) C. Y. Cheah et al. BLOOD
- AtypicalPneumocystis jiroveciipneumonia in previously untreated patients with CLL on single-agent ibrutinib
- (2016) Inhye E. Ahn et al. BLOOD
- ECIL guidelines for preventingPneumocystis jiroveciipneumonia in patients with haematological malignancies and stem cell transplant recipients
- (2016) Johan Maertens et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- Ibrutinib for Chronic Lymphocytic Leukemia
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib
- (2016) Julia A. Messina et al. Open Forum Infectious Diseases
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
- (2015) P. Jain et al. BLOOD
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients
- (2015) Anders Österborg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus
- (2015) S. Herbst et al. EMBO Molecular Medicine
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
- (2015) Marinus H J van Oers et al. LANCET ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis
- (2015) Xuqin Jiang et al. PLoS One
- Immunological Consequences of JAK Inhibition: Friend or Foe?
- (2015) Donal P. McLornan et al. Current Hematologic Malignancy Reports
- Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia
- (2014) Eric Tse et al. ANNALS OF HEMATOLOGY
- Update on Epidemiology of and Preventive Strategies for Invasive Fungal Infections in Cancer Patients
- (2014) J. R. Perfect et al. CLINICAL INFECTIOUS DISEASES
- Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014
- (2014) S. Fleming et al. INTERNAL MEDICINE JOURNAL
- Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma
- (2014) Chaitra Ujjani et al. LEUKEMIA & LYMPHOMA
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
- (2014) G Zugmaier et al. Blood Cancer Journal
- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study
- (2013) Russell E. Lewis et al. MYCOSES
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk stratification for invasive aspergillosis in immunocompromised patients
- (2012) Raoul Herbrecht et al. Annals of the New York Academy of Sciences
- Pneumocystis Pneumonia in Patients Treated With Rituximab
- (2012) Isabel Martin-Garrido et al. CHEST
- Epidemiology and Clinical Manifestations of Mucormycosis
- (2012) George Petrikkos et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy
- (2012) Dionissios Neofytos et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies
- (2012) Kamal D. Puri et al. Frontiers in Immunology
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
- (2011) Simone Lanini et al. BMC Medicine
- Fungal Infections in Leukemia Patients: How Do We Prevent and Treat Them?
- (2010) Konstantinos Leventakos et al. CLINICAL INFECTIOUS DISEASES
- Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab
- (2010) Toshiro Kurokawa et al. HEMATOLOGICAL ONCOLOGY
- Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients
- (2010) L. Pagano et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical risk factors for invasive aspergillosis
- (2010) John W. Baddley MEDICAL MYCOLOGY
- Rituximab-Associated Neutropenia
- (2010) Kieron Dunleavy et al. SEMINARS IN HEMATOLOGY
- Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma
- (2009) Gillianne Geet Yi Lai et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phosphoinositide 3-Kinase p110 Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses
- (2009) C. A. Durand et al. JOURNAL OF IMMUNOLOGY
- Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis
- (2009) Sercan Aksoy et al. LEUKEMIA & LYMPHOMA
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
- (2008) Ben De Pauw et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry
- (2008) D. Neofytos et al. CLINICAL INFECTIOUS DISEASES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started